tafasitamab (Monjuvi) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Fast Track FDA Breakthrough Therapy FDA Accelerated Approval FDA
AACT

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Drug Pricing (per unit)

United States

$912.5600
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

mor00208 | mor208

Organizations (19)

Research & Development (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Lymphoma, Large B-Cell, Diffuse (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Prolymphocytic (Phase 2)

Lymphoma, B-Cell (Phase 1/Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 3)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 29
  • # of Trial Organizations: 19

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue